21-Sept-2026 18:13:55

IND-SWIFT LABORATORIES : PREFERENTIAL ISSUE TO QIB

• Essix Biosciences Limited, along with its Promoter and Promoter Group (PACs), acquired 70,00,000 fully convertible warrants on September 17, 2026, on a preferential basis. • These warrants are convertible into equity shares of face value ₹10 each of Ind-Swift Laboratories Limited. • Prior to this acquisition, Essix Biosciences Limited and PACs held 3,28,82,521 shares and 44,51,757 shares respectively. • Post-acquisition, their holding of warrants stands at 70,00,000. Impact: Neutral (Disclosure of warrant acquisition under SEBI regulations)

Ind-Swift Laboratories Limited

← Back to feed